Dysregulation of hypothalamic modulation in olanzapine treated male rats

Basit Öğe Kaydı
dc.contributor.authorSezlev-Bilecen, Deniz
dc.contributor.authorAk, Mehmet
dc.contributor.authorYanik, Tulin
dc.date.accessioned2024-02-23T14:13:36Z
dc.date.available2024-02-23T14:13:36Z
dc.date.issued2016
dc.departmentNEÜen_US
dc.description.abstractThe mechanism of weight gain through application of olanzapine, a serotonin and dopamine receptor antagonist has not been fully understood. Weight gain and food intake are under the control of various neurohormones; POMC (proopiomelanocortin), CART (cocaine and amphetamine regulated transcript), AgRP (Agouti-related peptide) and NPY (neuropeptide Y) that are majorly synthesized and secreted from the arcuate nucleus (ARC) of hypothalamus. In this study, the alteration of the ARC neurohormone levels in rats were determined as one of the weight gain mechanisms. To understand the underlying mechanism of olanzapine-induced weight gain, the drug was orally administrated to healthy male Wistar rats for analysis of both the hypothalamic gene expression and peripheral levels of those candidate neuropeptides. In rats hypothalamic mRNA levels of NPY, AgRP and POMC decreased while CART levels did not show any alteration. Consistently, circulating levels of NPY, AgRP and alpha-MSH decreased significantly yet CART levels were also reduced. In conclusion, it may be presumed that the antagonistic effect of olanzapine on the ARC neurons might be the onset for a dysregulation of the neurohormones secretion which may cause weight gain during treatment. (C) 2016 Elsevier Inc. All rights reserved.en_US
dc.description.sponsorshipMiddle East Technical University, Ankara, Turkey [BAP-08-11-2010-021]; Gulhane School of Medicine, Ankara, Turkey [BAP-08-11-2010-021]en_US
dc.description.sponsorshipThere was no conflict of interest for this study. This research was supported by Middle East Technical University and Gulhane School of Medicine, Ankara, Turkey. Project number: BAP-08-11-2010-021.en_US
dc.identifier.doi10.1016/j.pnpbp.2016.06.012
dc.identifier.endpage107en_US
dc.identifier.issn0278-5846
dc.identifier.issn1878-4216
dc.identifier.pmid27353111en_US
dc.identifier.scopus2-s2.0-84977646062en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage103en_US
dc.identifier.urihttps://doi.org/10.1016/j.pnpbp.2016.06.012
dc.identifier.urihttps://hdl.handle.net/20.500.12452/12495
dc.identifier.volume71en_US
dc.identifier.wosWOS:000382204200013en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.ispartofProgress In Neuro-Psychopharmacology & Biological Psychiatryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAtypical Antipsychoticsen_US
dc.subjectOlanzapineen_US
dc.subjectHypothalamic Neuropeptidesen_US
dc.subjectWeight Gainen_US
dc.subjectSerotoninen_US
dc.subjectArcuate Nucleusen_US
dc.titleDysregulation of hypothalamic modulation in olanzapine treated male ratsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu